Panda.eth

35 lbs This guy is roughly 30% BF (body-fat) That means he has ~133 lbs of LBM (lean body mass) If he maintains essentially ALL of his LBM (which is generous btw)… He’d clock in at ~15% BF right around 155 Most dudes that look like this think they’ve only got 10-15 to lose!

How much weight do you think this guy needs to lose to get visible abs? For context, he's 5ft 11 and 190 lbs.

My tribe told me to add MOTS-c to my stack so like a good sheep I sourced some. Had to use grok to read up on it and it all sounds very scientific. Still not sure what it does, but I’m also not a pussy so we are a go for tomorrow. Could use some advice on starting dose from my fellow researchers. Drop suggestions below 👇 LFG!

Ashton Hall reveals he never trains abs despite having an insane six pack “I don’t do core. I didn’t do core for like 10 years. We all have a six pack, you just might not see it because of your diet. That’s why I do no carbs, the diet is for the core” “If you want a smaller waist, you don’t train core at all, you just make sure you’re in a caloric deficit so you can lose the fat over it”

Just spent over an hour with my clinical team debating which growth hormone peptide protocol to run. Still torn. Wanted to share the thinking and get your take. The goal: Increase GH and IGF-1 to support anabolism, recovery, and sleep, but also test a specific stacking hypothesis. Tirzepatide (GLP-1/GIP agonist) can elevate resting heart rate, disrupt sleep, and suppress appetite aggressively. CJC-1295 (GHRH analog) can worsen insulin resistance. The bet is that combining them cancels each other's downsides: CJC-1295's slow-wave sleep enhancement offsets tirzepatide's sleep disruption, while tirzepatide's insulin-sensitizing effects counteract CJC-1295's insulin resistance. Best of both worlds — or at least, that's the hypothesis we're testing. The two candidates: CJC-1295 with DAC: the long acting version. One injection per week, stays active for 6–8 days. This is what was used in the actual clinical trials. Raises GH 2–10x and IGF-1 1.5–3x from a single dose. Preserves GH pulsatility even under continuous stimulation. The tradeoff: if you get side effects, you're committed for a week. Harder to titrate. CJC-1295 without DAC + ipamorelin: the short-acting version paired with a selective ghrelin receptor agonist. Daily injections, pre-bed, clears in 30 minutes. Ipamorelin adds a second axis of GH release, pulse frequency via the ghrelin pathway, on top of the amplitude boost from CJC. No cortisol or prolactin elevation. This is what most clinicians prescribe and most of the peptide community uses. The tradeoff: less clinical trial data, daily injections, more anecdotal evidence base. What we're considering: Start with DAC at half dose 2.4 mg, then if well tolerated escalate 4.8 mg, weekly injection. If side effects aren't tolerable, switch to no-DAC + ipamorelin (100 mcg then 200-300 mcg daily, before bedtime). Or, Run both head to head. 2 weeks DAC, 2 weeks no-DAC + ipamorelin and compare. Tracking: GH, IGF-1, Cortisol, CGM, real time core body temperature, RHR, overnight HRV (rMSSD), IGF-1, HOMA-IR, sleep architecture, subjective recovery. The purist in us says stick with DAC; that's where the published data lives. Yet the pragmatist says no-DAC + ipamorelin is what thousands of people actually use, and testing it generates more socially relevant data.